Aristada (Aripiprazole Lauroxil) Patent Expiration, LOE Window & CMS Spending

Aristada (Aripiprazole Lauroxil) by Alkermes: FDA Orange Book core substance LOE 2030-10-26 (last listed 2039-04-06), 0 AB generics, $576.6M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAlkermes
FDA Application & PathwayN207533 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2030-10-26
Last Listed Patent or Exclusivity Date2039-04-06
Orange Book Patents (*PED Extensions)18 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$576.6M
2024 Medicare Part D Spend$269.1M
2024 Medicaid Spend$307.5M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Alkermes across sibling Meru public-data platforms.